Jennifer M. Yeh

Research Scientist
Harvard School of Public Health
Research Scientist
(617) 432-2019

Jennifer M. Yeh is a research scientist at the Center for Health Decision Science. Her research focuses on using decision-analytic and mathematical modeling methods to improve cancer control policies, with an emphasis on disparities and underserved populations. She graduated from the University of Colorado at Boulder in 1996 with a B.A. in Biology, received an M.S. in Health Policy and Management from the Harvard School of Public Health in 2001, and completed her doctorate from the Health Policy PhD program at Harvard University, concentrating in Decision Sciences, in 2007. She is a current recipient of a National Cancer Institute K07 Career Development Award to evaluate risk factor-focused and technology-based interventions to improve gastric cancer outcomes. Before returning to school to pursue her doctorate, she worked at Abt Associates Inc. where she designed a variety of economic and quality of life studies in the Clinical Trials Department. Her current research focuses on gastric cancer prevention, childhood cancer survivorship, and cancer disparities.

Posted on April 22, 2013
Authors: Chen SC, Toy M, Yeh J, Wang JD, Resch S
Pediatrics 2013 131(4)  DOI: 10.1542/peds.2012-1262



To compare the cost-effectiveness of hepatitis B virus (HBV) control strategies combining universal vaccination with hepatitis B immunoglobulin (HBIG) treatment for neonates of carrier mothers.


<... (more »)
Posted on July 27, 2012
Authors: Yeh J, Diller L
Blood 2012  PubmedID: 22826564

As pediatric Hodgkin's Lymphoma (HL) survival rates approach >95%, treatment decisions are increasingly based upon minimizing late-effects. Using a model-based approach, we explored whether the addition of radiotherapy contributes to improved o... (more »)

Posted on May 1, 2010
Authors: Yeh J, Nekhlyudov L, Goldie S, Mertens AC, Diller L
Annals of Internal Medicine 2010 152(7): 409-17  PubmedID: 20368646

BACKGROUND: Although childhood cancer survival rates have dramatically increased, survivors face elevated risk for life-threatening late effects, including secondary cancer. OBJECTIVE: To estimate the cumulative effect of disease- and treatment... (more »)

Posted on June 23, 2010
Authors: Yeh J, Hur C, Kuntz KM, Ezzati M, Goldie S
Cancer 2010 116(12): 2941-53  PubmedID: 20564399   DOI: 10.1002/cncr.25030

Although surveillance for Barrett esophagus and other gastrointestinal precancerous conditions is recommended, no analogous guidelines exist for gastric lesions. The objective of this study was to estimate the clinical benefits and cost-effecti... (more »)

Posted on February 1, 2010
Authors: Yeh JM, Goldie SJ, Kuntz KM, Ezzati M
Cancer causes & control : CCC 2009  PubmedID: 19642005   ISSN/ISBN: 1573-7225   DOI: 10.1007/s10552-009-9397-9
OBJECTIVE: Although gastric cancer incidence is declining in China, trends may differ from historical patterns in developed countries. Our aim was to (1) retrospectively estimate the effects of Helicobacter pylori (H. pylori) and smoking on past gast... (more »)
Posted on February 1, 2010
Authors: Yeh Jennifer M, Kuntz Karen M, Ezzati Majid, Goldie Sue J
International Journal of Cancer 2009 124(1): 157-166  PubmedID: 261665000000   ISSN/ISBN: 0020-7136   DOI: 10.1002/ijc.23864
Gastric cancer is the second leading cause or cancer-related deaths worldwide. Treatment for Helicobacter pylori infection, the leading causal risk factor, can reduce disease progression, but the long-term impact on cancer incidence is uncertain, Usi... (more »)
Posted on February 1, 2010
Authors: Yeh Jennifer M, Kuntz Karen M, Ezzati Majid, Hur Chin, Kong Chung Yin, Goldie Sue J
Cancer Epidemiology Biomarkers & Prevention 2008 17(5): 1179-1187  PubmedID: 256013000000   ISSN/ISBN: 1055-9965   DOI: 10.1158/1055-9965.EPI-07-2539
Although epidemiologic studies have established the relationship between Helicobacter pylori and gastric cancer and promising results that H. pylori treatment can reduce cancer incidence among individuals without preexisting precancerous lesions, the... (more »)
Posted on February 1, 2010
Authors: Yeh JM, Hook EW, Goldie SJ
Sexually transmitted diseases 2003 30(5): 369-378  PubmedID: 183048000000   ISSN/ISBN: 0148-5717
Background: The major complications of pelvic inflammatory disease (infertility, ectopic pregnancy, and chronic pelvic pain) are the leading cause of non-HIV sexually transmitted disease morbidity in the United States. Goal. The goal of the study was... (more »)
Posted on February 1, 2010
Authors: Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL
Quality of Life Research 2002 11(4): 317-327  PubmedID: 175764000000   ISSN/ISBN: 0962-9343
Posted on February 1, 2010
Authors: Yeh JM, Botteman M, Pashos CL, Postma MJ, Staginnus U
Infusion Therapy and Transfusion Medicine-Infusionstherapie Und Transfusionsmedizin 2002 29(4): 218-225  PubmedID: 177632000000   ISSN/ISBN: 1424-5485
Posted on February 1, 2010
Authors: Lewis TS, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing KA, Ahn NG
Molecular cell 2000 6(6): 1343-1354  PubmedID: 166240000000   ISSN/ISBN: 1097-2765

Childhood Cancer Survivorship

Over the past decades, survival rates for childhood cancer have dramatically increased, with over 300,000 long-term survivors alive today.

Disparities in Cancer Prevention and Control

Much of the disparity in cancer outcome is a reflection of type, timeliness, and continuity of cancer care rather than the disease itself

Gastric Cancer Prevention

Finding effective primary and secondary prevention strategies can significantly reduce gastric cancer mortality in the U.S. and globally.